Your browser doesn't support javascript.
loading
Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi, Nusrat J; Richard, Stephanie A; Lindholm, David A; Mende, Katrin; Ganesan, Anuradha; Huprikar, Nikhil; Lalani, Tahaniyat; Fries, Anthony C; Maves, Ryan C; Colombo, Rhonda E; Larson, Derek T; Smith, Alfred; Chi, Sharon W; Maldonado, Carlos J; Ewers, Evan C; Jones, Milissa U; Berjohn, Catherine M; Libraty, Daniel H; Edwards, Margaret Sanchez; English, Caroline; Rozman, Julia S; Mody, Rupal M; Colombo, Christopher J; Samuels, Emily C; Nwachukwu, Princess; Tso, Marana S; Scher, Ann I; Byrne, Celia; Rusiecki, Jennifer; Simons, Mark P; Tribble, David; Broder, Christopher C; Agan, Brian K; Burgess, Timothy H; Laing, Eric D; Pollett, Simon D.
Afiliación
  • Epsi NJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Richard SA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Lindholm DA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Mende K; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Ganesan A; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Huprikar N; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Lalani T; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Fries AC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Maves RC; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Colombo RE; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Larson DT; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Smith A; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Chi SW; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Maldonado CJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Ewers EC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Jones MU; Naval Medical Center Portsmouth, Portsmouth, Virginia, USA.
  • Berjohn CM; US Air Force School of Aerospace Medicine, Dayton, Ohio, USA.
  • Libraty DH; Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Edwards MS; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • English C; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Rozman JS; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Mody RM; Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA.
  • Colombo CJ; Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA.
  • Samuels EC; Naval Medical Center San Diego, San Diego, California, USA.
  • Nwachukwu P; Naval Medical Center Portsmouth, Portsmouth, Virginia, USA.
  • Tso MS; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Scher AI; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Byrne C; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Rusiecki J; Womack Army Medical Center, Fort Bragg, North Carolina, USA.
  • Simons MP; Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA.
  • Tribble D; Tripler Army Medical Center, Honolulu, Hawaii, USA.
  • Broder CC; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Agan BK; Naval Medical Center San Diego, San Diego, California, USA.
  • Burgess TH; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Laing ED; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Pollett SD; Naval Medical Center San Diego, San Diego, California, USA.
Clin Infect Dis ; 76(3): e439-e449, 2023 02 08.
Article en En | MEDLINE | ID: mdl-35608504
ABSTRACT

BACKGROUND:

Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity.

METHODS:

We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.

RESULTS:

Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01).

CONCLUSIONS:

Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos